कंपनी का अवलोकन
Kezar Life Sciences, Inc. is a clinical-stage biotechnology entity focused on the discovery and development of novel small molecule therapeutics aimed at addressing unmet medical needs in immune-mediated diseases within the United States. The company operates within the healthcare sector, specifically functioning in the biotechnology industry, which implies a focus on high-risk, high-reward R&D activities and potential for significant innovation in therapeutic modalities. As of the latest data, the firm possesses a market capitalization of $54.18M and maintains a workforce comprising 9 employees, reflecting a lean organizational structure typical of early-stage biotech ventures. The market cap of $54.18M indicates a small-cap positioning, suggesting the company is still in a growth or development phase where valuation is driven more by pipeline potential and intellectual property assets rather than established commercial revenue streams, while the absence of reported revenue underscores its status as a pre-commercial or clinical-stage entity reliant on external funding or asset monetization.
वित्तीय स्वास्थ्य
The financial statements for Kezar Life Sciences, Inc. reveal a Net Income of $-56,033,000 and an EBITDA of $-51,373,000 over the trailing twelve months, while the Revenue figure is not available in the current dataset. The substantial gap between the reported net income of $-56,033,000 and the EBITDA of $-51,373,000 highlights a significant impact from non-operating expenses, interest, taxes, or other comprehensive income/loss items that are not captured in the EBITDA metric, indicating a cost structure where overheads or financing costs are material to the bottom line. The company reported Free Cash Flow of $-29,152,250, which signifies a heavy burn rate typical for clinical-stage companies, indicating limited financial flexibility until product candidates advance to later stages of development or achieve commercialization. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet generated commercial sales volume sufficient to realize positive gross profitability or operating leverage. On the liability side, the company holds Cash of $71.88M against a Debt obligation of $2.33M, resulting in a Debt to Equity ratio of 3.32, which suggests a balance sheet that is currently unleveraged in terms of traditional debt usage but carries significant cash reserves relative to its small equity base. The Current Ratio stands at 11.52, indicating an exceptionally strong short-term liquidity position where current assets vastly exceed current liabilities, providing ample room to fund operations without immediate refinancing pressure. Return on Equity is -59.9% and Return on Assets is -29.5%, metrics that reveal management is currently utilizing the company's capital base to generate negative returns, a common characteristic in R&D-intensive biotechnology firms before a successful product launch can reverse these figures.
मूल्यांकन आकलन
The valuation metrics for Kezar Life Sciences, Inc. present a Trailing P/E Ratio of N/A and a Forward P/E of -2.76, implying that the market cannot value the stock based on current earnings due to the significant losses, while the negative forward P/E suggests analysts project continued negative earnings or a very low earnings base in the immediate future. The Price to Book ratio is 0.77, indicating that the market values the company at 77% of its book value, which may suggest the market is pricing in the high risk of the clinical-stage assets or that the book value includes significant intangible assets not yet realized. The Price to Sales ratio is N/A and the EV/EBITDA is 0.30, suggesting that traditional revenue-based valuation methods are not applicable due to lack of sales, while the low EV/EBITDA multiple reflects the company's negative earnings and the market's assessment of its intrinsic value based on enterprise value relative to adjusted earnings. The 52-Week High is $7.55 and the 52-Week Low is $3.53, and without a specific current price provided in the facts, the stock's trading range indicates a volatility band of approximately $4.02 within which the asset has moved recently. The Beta value is 0.43, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting that Kezar Life Sciences moves less than the S&P 500 or similar indices, offering a lower correlation to general market swings despite its small-cap classification.
Growth & Income
The Revenue Growth Year-Over-Year and Earnings Growth Year-Over-Year are both listed as N/A, preventing a direct comparison of earnings growth versus revenue growth since commercial revenue is not yet realized in the available data. Consequently, the company does not currently pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the firm retains all its cash flow to fund research, development, and operational expenses rather than distributing income to shareholders. In the absence of dividend payments, the company's strategy relies on reinvesting available Cash of $71.88M into its pipeline of novel small molecule therapeutics to advance clinical trials and potentially achieve commercial milestones. The overall growth and income profile for Kezar Life Sciences, Inc. is characterized by a lack of historical revenue growth metrics and a zero-dividend policy, focusing entirely on capitalizing the business through internal cash reserves and external financing to progress its clinical-stage product candidates.